Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Armin Ghobadi et al. published in eClinical Medicine:
“Advancing CAR T-Cell Therapy: Faster and Effective for Lymphoma Patients.
A phase I clinical trial evaluated the safety and feasibility of point-of-care CAR T-cell manufacturing, significantly reducing the time from apheresis to infusion (median: 13 days).
Key Findings:
- High Response Rates: 86% overall response, 76% complete response
- Survival Outcomes: 2-year progression-free survival: 63%, overall survival: 68%
- Comparable Safety Profile: CRS (65%), ICANS (32%), with a recommended phase 2 dose of 2 × 10⁶ MB-CART-19 cells/kg
Faster manufacturing could improve access for patients with rapidly progressing lymphoma – a critical step in personalized cancer treatment.”
Authors: Armin Ghobadi, Paolo Caimi, Jane Reese, Boro Dropulic, Marcos de Lima et al.
More posts featuring Yan Leyfman.